Although AbbVie has lost patent exclusivity for its flagship drug, Humira, the company may soon be bigger and better.

Because AVUS is an ETF, it's best compared with Vanguard's Total Stock Market Index ETF VTI. In that same period, the cumulative gain for VTI was 91.9%. Although that outperformance by AVUS is far ...

Kinder Morgan's (NYSE: KMI) dry spell has come to an end. The natural gas pipeline company had struggled to grow in recent ...

We are recommending PepsiCo and Target for investment in 2025 due to suppressed valuations and potential for growth amid ...

Five magnificent income stocks -- sporting an average yield of 4.26% -- can pad investors' pocketbooks in the new year (and well beyond).

CHINESE firms are attracting investors with increased dividends and buybacks, spurred by a policy push for corporate ...

A big question for UK investors is how much to pump into shares with the aim of achieving meaningful passive income down the ...

Here are three stocks with buy rank and strong income characteristics for investors to consider today, January 24th: ICL ...

IAG shares have been one of the best performers on the FTSE 100 over the past six months. Dr James Fox has several key ...

Despite the weakness in the secondary market, shares of Hindustan Zinc have rallied over 13 per cent over the past fortnight ...

As global markets experience a rebound, driven by easing core U.S. inflation and strong bank earnings, investors are increasingly turning their attention to dividend stocks for potential stability and ...